AstraZeneca (AZN), the UK-listed drug maker, is undervalued according to Stephen Bailey, a macro fund manager at Liontrust.
IC TIP:
Buy
After AstraZeneca rejected a takeover offer from American drug giant Pfizer (PFZ) to buy its shares for £55 each, their value has fallen back to a level which does not reflect the company's "substantial" pipeline potential, he says.